周  倩  博士 副研究员 硕士生导师

  邮 箱：zhouqian@hainanu.edu.cn

  1.教育背景

  2017.08—2022.06，中山大学， 药物化学，理学博士；

  2013.08—2017.06，中山大学， 药学，理学学士；

  2.科研情况

  课题组以磷酸二酯酶为靶标，结合海南丰富独特的黎药与海洋药物资源，进行新型PDE小分子抑制剂开发、适应症探索以及机制研究。目前已在APSB、J. Med. Chem、J. Enzym. Inhib. Med. Chem.等SCI期刊发表论文20篇，其中以第一作者发表7篇。申请专利9项，其中授权8项。

  3.研究方向

  靶向神经炎症的抗神经退行性疾病的创新药物研究

  靶向PDE的抗纤维化药物发现与分子机制研究

4.代表性成果

[1]Zhou Q^#; Le M L^#; Yang Y Y; Wang W J; Huang Y Q; Wang Q; Tian Y J; Jiang M Y; Rao Y^*; Hai-BinLuo^*; YinuoWu^*, Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis,Acta Pharmaceutica Sinica B,2022. (IF: 14.903)

[2] Wu X N^#,Zhou Q^#, Huang Y D, Xie X, Li Z, Wu Y^*, Luo H B^*. Structure-Based Discovery of Orally Efficient Inhibitors via Unique Interactions with H-pocket of PDE8 for the Treatment of Vascular Dementia[J].Acta Pharmaceutica Sinica B,2022,12(7): 3103–3112. (IF: 14.903)

[3] Wu Y N^#,Zhou Q^#, Zhang T H^#, Zhe Li, Chen Y P, Zhang P, Yu Y F, Geng H j, Tian Y J, Zhang C, Wang Y, Chen J W,^*Chen Y^*, Luo H B^*. Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia[J].Journal of Medicinal Chemistry,2019, 62(8): 4218−4224. (IF:6.205)

[4] Huang Y D^#, Wu X N^#,Zhou Q^#, Wu Y N, Zheng D X, Li Z, Guo L; Luo H B^*. Rational Design of 2-Chloroadenine Derivatives as Highly Selective Phosphodiesterase 8A Inhibitors [J].Journal of Medicinal Chemistry,2020, 63(24): 15852-15863. (IF:7.446)

[5] Liang J^#, Huang Y Y^#,Zhou Q^#, Gao Y Q, Li Z, Wu D Y, Si Yu, Guo L, Chen Z, Huang L, Liang Steven H., He X X^*, Wu R B^*, Luo H B^*. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia[J].Journal of Medicinal Chemistry,2020, 63(6): 3370–3380. (IF: 7.446)

[6] Yang Y C^#, Zhang S R^#,Zhou Q^#, Zhang C, Gao Y Q, Wang H, Li Z, Wu D Y, Wu Y N, Huang Y Y^*, Guo L^*, Luo H B^*. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension[J].Acta Pharmaceutica Sinica B,2020, 10(12): 2339-2447. (IF: 11.413)

[7] Zhang C^#,Zhou Q^#, Wu X N, Huang Y-D, Zhou J, Lai Z W^*, Wu Y N^*, Luo H B^*. Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer's disease[J].Journal of Enzyme Inhibition and Medicinal Chemistry,2018, 33(1):260-270. (IF: 4.673)

[8]罗海彬;吴旭年;黄雅丹;周倩;一种2-氯腺嘌呤衍生物、制备方法及应用, 2022-03-25,中国, CN202011126602.3.

[9]罗海彬;黄仪有;李哲;周倩;托芬那酸或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒炎症药物中的应用, 2022-02-01,中国，CN202010105310.5.

[10]罗海彬;王鑫;李哲;黄仪有;周倩;坎地沙坦酯或其药学上可接受的盐在制备预防和/或治疗新型冠状病毒肺炎药物中的应用, 2022-02-01,中国, CN202010160616.0.

[11]罗海彬;吴德燕;姜赞;黄仪有;周倩;黄雅丹;一种取代吲哚并氮杂酮类化合物及其制备方法和应用, 2022-07-26,中国, CN202010660872.6.

[12]罗海彬;吴一诺;张佩;周倩;陈仪萍;张天华;于艳发;吴旭年;一类N-取代吡唑并[3,4-d]嘧啶酮类化合物及其制备方法和应用, 2021-05-14,中国, CN201810858465.9.